128 related articles for article (PubMed ID: 37442742)
1. Sarcopenia assessments as predictors of overall survival in patients with metastatic renal cell carcinoma.
Kümmerl L; Kraulich M; Lesyuk W; Binninger A; Goebell PJ; Kahlmeyer A
Urol Oncol; 2023 Sep; 41(9):392.e1-392.e9. PubMed ID: 37442742
[TBL] [Abstract][Full Text] [Related]
2. Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study.
Ueki H; Hara T; Okamura Y; Bando Y; Terakawa T; Furukawa J; Harada K; Nakano Y; Fujisawa M
Investig Clin Urol; 2022 Jul; 63(4):415-424. PubMed ID: 35796138
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of Sarcopenia in Patients with Metastatic Renal Cell Carcinoma.
Fukushima H; Nakanishi Y; Kataoka M; Tobisu K; Koga F
J Urol; 2016 Jan; 195(1):26-32. PubMed ID: 26292042
[TBL] [Abstract][Full Text] [Related]
4. Impact of sarcopenia on post-operative outcomes following nephrectomy and tumor thrombectomy for renal cell carcinoma with inferior vena cava thrombus.
Watanabe S; Ishihara H; Takagi T; Kondo T; Ishiyama R; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Apr; 51(5):819-825. PubMed ID: 33558883
[TBL] [Abstract][Full Text] [Related]
5. Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Khan AI; Psutka SP; Patil DH; Hong G; Williams MA; Bilen MA; Sekhar A; Kissick HT; Narayan VM; Joshi SS; Ogan K; Master VA
Cancer; 2022 Jun; 128(11):2073-2084. PubMed ID: 35285950
[TBL] [Abstract][Full Text] [Related]
6. Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma.
Aslan V; Kılıç ACK; Sütcüoğlu O; Eraslan E; Bayrak A; Öksüzoğlu B; Tahtacı G; Özdemir N; Üner A; Günel N; Özet A; Yazıcı O
Urol Oncol; 2022 Nov; 40(11):494.e1-494.e10. PubMed ID: 36137881
[TBL] [Abstract][Full Text] [Related]
7. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
8. Dorsal Muscle Attenuation May Predict Failure to Respond to Interleukin-2 Therapy in Metastatic Renal Cell Carcinoma.
Otemuyiwa B; Derstine BA; Zhang P; Wong SL; Sabel MS; Redman BG; Wang SC; Alva AS; Davenport MS
Acad Radiol; 2017 Sep; 24(9):1094-1100. PubMed ID: 28341412
[TBL] [Abstract][Full Text] [Related]
9. Sarcopenia Is Associated With Aggressive Clinicopathological Outcomes and Is a Poor Prognostic Indicator for Non-metastatic Renal Cell Carcinoma.
Makino T; Izumi K; Iwamoto H; Kadomoto S; Kadono Y; Mizokami A
In Vivo; 2023; 37(3):1304-1311. PubMed ID: 37103104
[TBL] [Abstract][Full Text] [Related]
10. Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma.
Higgins MI; Martini DJ; Patil DH; Nabavizadeh R; Steele S; Williams M; Joshi SS; Narayan VM; Sekhar A; Psutka SP; Ogan K; Bilen MA; Master VA
Cancer; 2021 Jun; 127(12):1974-1983. PubMed ID: 33760232
[TBL] [Abstract][Full Text] [Related]
11. Validation of a deep learning segmentation algorithm to quantify the skeletal muscle index and sarcopenia in metastatic renal carcinoma.
Roblot V; Giret Y; Mezghani S; Auclin E; Arnoux A; Oudard S; Duron L; Fournier L
Eur Radiol; 2022 Jul; 32(7):4728-4737. PubMed ID: 35304638
[TBL] [Abstract][Full Text] [Related]
12. Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma.
Colomba E; Alves Costa Silva C; Le Teuff G; Elmawieh J; Afonso D; Benchimol-Zouari A; Guida A; Derosa L; Flippot R; Raynard B; Escudier B; Bidault F; Albiges L
J Cachexia Sarcopenia Muscle; 2022 Oct; 13(5):2405-2416. PubMed ID: 35903892
[TBL] [Abstract][Full Text] [Related]
13. A lower psoas muscle volume was associated with a higher rate of recurrence in male clear cell renal cell carcinoma.
Noguchi G; Kawahara T; Kobayashi K; Tsutsumi S; Ohtake S; Osaka K; Umemoto S; Nakaigawa N; Uemura H; Kishida T; Yao M
PLoS One; 2020; 15(1):e0226581. PubMed ID: 31895931
[TBL] [Abstract][Full Text] [Related]
14. Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
Vashi PG; Gorsuch K; Wan L; Hill D; Block C; Gupta D
PLoS One; 2019; 14(6):e0218761. PubMed ID: 31220163
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
[TBL] [Abstract][Full Text] [Related]
16. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Sharma P; Zargar-Shoshtari K; Caracciolo JT; Fishman M; Poch MA; Pow-Sang J; Sexton WJ; Spiess PE
Urol Oncol; 2015 Aug; 33(8):339.e17-23. PubMed ID: 26094169
[TBL] [Abstract][Full Text] [Related]
17. Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Song Y; Du C; Zhang W; Sun Y; Yang L; Cui C; Chi Y; Shou J; Zhou A; Wang J; Sun Y
Urol Oncol; 2016 Jun; 34(6):258.e15-22. PubMed ID: 26803435
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer.
Ikeda T; Ishihara H; Iizuka J; Hashimoto Y; Yoshida K; Kakuta Y; Takagi T; Okumi M; Ishida H; Kondo T; Tanabe K
Jpn J Clin Oncol; 2020 Aug; 50(8):933-939. PubMed ID: 32303747
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder.
Stangl-Kremser J; D'Andrea D; Vartolomei M; Abufaraj M; Goldner G; Baltzer P; Shariat SF; Tamandl D
Urol Oncol; 2019 Jun; 37(6):372-379. PubMed ID: 30578161
[TBL] [Abstract][Full Text] [Related]
20. Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.
Miyake H; Miyazaki A; Imai S; Harada K; Fujisawa M
Target Oncol; 2016 Apr; 11(2):175-82. PubMed ID: 26341668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
